{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"334"}],"units":"Participants"}],"title":"Pre-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"330"}],"units":"Participants"}],"title":"On-treatment"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Crossover On-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"218"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"298"}],"units":"Participants"}],"title":"Post-treatment survival follow-up"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Crossover post-treatment survival follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"221"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"334"}],"units":"Participants"}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"334"}],"units":"Participants"}],"description":"Pre-treatment deaths were collected from randomization to the day before first dose of study medication.\n\nOn-treatment deaths were collected from start of treatment to 30 days after last dose of treatment or one day before first administration of crossover treatment (for crossover participants), whichever came first Crossover on-treatment deaths were collected from start of crossover treatment up to 30 days after last dose of crossover treatment.\n\nPost-treatment survival follow-up (FU) deaths were collected from day 31 after last dose of study treatment to end of study.\n\nCrossover post-treatment survival FU deaths were collected from day 31 after last dose of crossover treatment to end of study","groups":[{"description":"Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with letrozole 2.5 mg daily oral","id":"OG000","title":"Ribociclib + Letrozole"},{"description":"Placebo daily oral (3 weeks on/ 1 week off) in combination with letrozole 2.5 mg daily oral.\n\nParticipants were unblinded once the final OS analysis was completed and after the implementation of protocol amendment 10 (30-Apr-21) and were given the option to crossover to treatment with ribociclib + letrozole","id":"OG001","title":"Placebo + Letrozole"}],"paramType":"NUMBER","populationDescription":"FAS including all randomized participants","reportingStatus":"POSTED","timeFrame":"Pre-treatment: Up to 21 days. On-treatment: Up to 99 months. Crossover on-treatment: Up to 12 months after crossing-over.Post-treatment survival FU: Up to 99 months.Crossover post-treatment survival FU: Up to 12 months after crossing-over","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}